| Identification | Back Directory | [Name]
FK-614 | [CAS]
193012-35-0 | [Synonyms]
FK-614
ATx-08001
ATx-08-001
3-[(2,4-DICHLOROPHENYL)METHYL]-2-METHYL-N-PENTYLSULFONYLBENZIMIDAZOLE-5-CARBOXAMIDE
1H-Benzimidazole-6-carboxamide, 1-[(2,4-dichlorophenyl)methyl]-2-methyl-N-(pentylsulfonyl)- | [Molecular Formula]
C21H23Cl2N3O3S | [MDL Number]
MFCD07772192 | [MOL File]
193012-35-0.mol | [Molecular Weight]
468.4 |
| Chemical Properties | Back Directory | [density ]
1.37±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 100 mg/mL (213.49 mM; Need ultrasonic) | [form ]
Solid | [pka]
2.53±0.40(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
FK 614 is a novel non-??thiazolidinedione (TZD) peroxisome proliferator-??activated receptor (PPAR) γ agonist, that ameliorates insulin resistance in Zucker fatty rats. | [in vivo]
FK614 (0.32~3.2 mg/kg; p.o.; 14 days) dose-dependently reduces plasma glucose level[3].
FK614 (0.1~10 mg/kg; p.o.; 14 days) improves the impaired glucose tolerance[3]. | Animal Model: | db/db Mice | | Dosage: | 0.1~10 mg/kg | | Administration: | P.o. | | Result: | Improved the impaired glucose tolerance.
|
| Animal Model: | db/db Mice | | Dosage: | 0.32~3.2 mg/kg | | Administration: | P.o. | | Result: | Dose-dependently reduced plasma glucose level.
|
| [IC 50]
PPAR-γ | [storage]
Store at -20°C |
|
| Company Name: |
Wuhan Topule
|
| Tel: |
+86-02787215551 +86-19945035818 |
| Website: |
http://www.topule.com/ |
|